Zoetis Inc. $ZTS Shares Sold by J. Safra Sarasin Holding AG

Key Points

• J. Safra Sarasin Holding AG reduced its stake in Zoetis by 5.6% during the second quarter, selling 12,404 shares, leaving them with 209,740 shares valued at approximately $32.7 million.
• Zoetis reported $1.76 earnings per share (EPS) for the last quarter, exceeding the consensus estimate of $1.62, with a net margin of 27.83% and revenue growth of 4.2% year-over-year.
• The consensus analyst rating for Zoetis is a Moderate Buy with a price target averaging around $200.88 following multiple adjustments from various research firms.

J. Safra Sarasin Holding AG cut its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 5.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 209,740 shares of the company's stock after selling 12,404 shares during the quarter. J. Safra Sarasin Holding AG's holdings in Zoetis were worth $32,709,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Lindbrook Capital LLC grew its holdings in Zoetis by 1.8% in the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock valued at $612,000 after purchasing an additional 65 shares during the period. Scott & Selber Inc. grew its stake in shares of Zoetis by 0.6% in the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company's stock valued at $1,817,000 after buying an additional 67 shares in the last quarter. Secure Asset Management LLC lifted its position in shares of Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company's stock worth $382,000 after purchasing an additional 68 shares in the last quarter. Quotient Wealth Partners LLC boosted its position in Zoetis by 2.3% in the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock valued at $521,000 after buying an additional 72 shares during the last quarter. Finally, Broadway Wealth Solutions Inc. grew its stake in shares of Zoetis by 4.4% during the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock valued at $287,000 after acquiring an additional 73 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

Zoetis stock opened at $146.87 on Thursday. The company has a market cap of $65.09 billion, a PE ratio of 25.28, a P/E/G ratio of 2.35 and a beta of 0.90. The company has a fifty day moving average price of $150.02 and a two-hundred day moving average price of $155.39. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $196.55.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the previous year, the company posted $1.56 earnings per share. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler upped their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Finally, Argus reaffirmed a "buy" rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.